IL2 and cancer: IL-21 is another cytokine from the IL-2-family that is also being actively tested in cancer clinical trials alone (NCT00095108, NCT00514085 and NCT00336987) or in combination with ipilimumab (NCT01489059), nivolumab (NCT01629758), sunitinib (NCT00617253), rituximab (NCT00347971), sorafenib (NCT00389285) or doxorubicin (NCT00523380).